Ticagrelor · Brilinta
Small molecule
Evidence outlook
Approved: Atherosclerotic Cardiovascular Disease, Acute Ischemic Stroke
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (4)
- Acute Coronary Syndrome or a History of Myocardial Infarction BRILINTA is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ] .
- Coronary Artery Disease but No Prior Stroke or Myocardial Infarction BRILINTA is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ] . While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM).
- Treatment of:
- Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event Brilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
EUCLID NCT01732822 · Atherosclerotic Cardiovascular Disease This was a large, randomized, quadruple-blind, active-controlled trial of 13,885 participants, using cardiovascular death, myocardial infarction, or ischemic stroke as a hard clinical primary endpoint. The primary comparison was not statistically significant: 751 events with ticagrelor versus 740 with clopidogrel (hazard ratio 1.02, 95% CI 0.92–1.13; p=0.650), so the results provide well-controlled but inconclusive evidence for ticagrelor's benefit in this population. Registry: NCT01732822 | 3 | Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke (From randomization to PACD, an average of 2.5 years) 2016-09-26 | Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke (From randomization to PACD, an average of 2.5 years): Ticagrelor 90 mg bd 751 Participants | Clopidogrel 75 mg od 740 Participants | Partial signal | link ↗ |
View 4 more trials
NCT01294462 NCT01294462 · Atherosclerotic Cardiovascular Disease Registry: NCT01294462 | 3 | Major Bleeding (Ongoing up to12 months); Major Adverse Cardiac Events (MACE) (Ongoing up to 12 months) 2012-07 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
PLATO NCT00391872 · Atherosclerotic Cardiovascular Disease Patients were randomly assigned to ticagrelor or the active comparator clopidogrel, with patients, doctors and outcome assessors blinded, and ticagrelor significantly reduced the combined rate of vascular death, heart attack or stroke at 12 months (hazard ratio 0.84, P<0.001). Neither the registry record nor the published abstract reports a power calculation, so it cannot be shown that the 18,624 patients enrolled matched a planned sample size. Registry: NCT00391872 | 3 | Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke (Randomization up to 12 months); Participants With Any Major Bleeding Event (First dosing up to 12 months) 2009-03 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
PEGASUS NCT01225562 · Myocardial Infarction Patients were randomly assigned to one of two ticagrelor doses or placebo, with patients, doctors and outcome assessors blinded, and both doses significantly reduced the combined rate of cardiovascular death, heart attack or stroke (hazard ratios 0.85 and 0.84). The sources we could check describe a target of 1,360 primary events but report no power calculation, so it cannot be shown that the trial was adequately sized. Registry: NCT01225562 | 3 | Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization (Randomization up to 47 months); Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients (First dosing up to 48 months) 2014-12 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
THEMIS NCT01991795 · Diabetes Mellitus, Type 2 Registry: NCT01991795 | 3 | Composite of Cardiovascular (CV) Death, MI or Stroke (From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.) 2019-01-25 | Composite of Cardiovascular (CV) Death, MI or Stroke (From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.): Ticagrelor 60 mg 736 Number of participants with event | Ticagrelor Placebo 818 Number of participants with event | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (80)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (31)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (37)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (186)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (40)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (14)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (8)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
Other P2Y12 receptor drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Acute Ischemic Stroke: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ticagrelor (Brilinta): this drug | Approved | Small molecule | P2Y12 receptor | Reliable signal | NCT03354429: Composite of Subsequent Stroke or Death (From randomisation (day 1) to visit 3 (day 30-34)): TICAGRELOR 303 Participants | PLACEBO 362 Participants | |
| Edaravone (TTYP01) | Phase 3 | Small molecule | oxidative stress | not yet graded | No reviewed efficacy summary in this indication | |
| Rinvecalinase Alfa | Phase 2/3 | Protein / enzyme therapeutic | Tissue kallikrein-1 (KLK1) | not yet graded | No reviewed efficacy summary in this indication | |
| Apadamtase Alfa (Adzynma) | Phase 2 | Protein / enzyme therapeutic | ADAMTS13 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4029 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-7450 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-8829 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(23 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Brilinta (Ticagrelor) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.